Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Cassava Sciences Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.87 (market cap $1.69B), while Cassava Sciences Inc trades at $1.18 (market cap $57.49M). The key difference: AMC ENTERTAINMENT HOLDINGS, INC. is far larger — about 29.4× Cassava Sciences Inc's market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| AMC | FLNA | |
|---|---|---|
Market Cap | $1.69B | $57.49M |
Sector | Media | Health |
52-Week High | $3.54 | $4.64 |
52-Week Low | $0.95 | $1.16 |
Enterprise Value | $9.28B | -$29.09M |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $1.89, down 0.53% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of -$0.36, missing expectations, while revenue trends show modest growth from $4.6B in 2024 to $4.85B in 2025. Recent news highlights box office recovery optimism and a $200 million stock offering that caused dilution concerns.
Outlook remains challenging with persistent net losses and high debt burden, though analyst consensus targets $1.90 with 32% buy ratings. Key risks include ongoing dilution from equity offerings, competitive pressures in entertainment, and the need for sustained box office recovery to improve cash flow and profitability.
FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.
While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
